



## Jeffrey Leiden, M.D., Ph.D.

### Executive Chairman

Jeffrey Leiden, M.D., Ph.D., is a physician and scientist who has dedicated his career to improving the lives of people with serious diseases. He currently serves as Vertex's Executive Chairman and was the Chief Executive Officer and President from 2012 through March 2020. He has been a member of Vertex's board of directors since July 2009, chairman of the board of directors since May 2012, and served as lead independent director from October 2010 through December 2011. Under his leadership, Vertex delivered the first and only medicines to treat the underlying cause of cystic fibrosis for patients with certain forms of the disease including KALYDECO®, ORKAMBI® and TRIKAFTA®.

As CEO, Dr. Leiden also built a robust pipeline of drug candidates in specialty markets, including pain, sickle cell disease, and type 1 diabetes, with a particular focus on therapies that cure or modify the course of disease. In 2015, he established a collaboration with CRISPR Therapeutics to develop a clinical program which is currently investigating the first potentially curative human gene-editing therapy for sickle cell disease and beta thalassemia. In 2019, he led the Vertex acquisition of Semma Therapeutics to develop a clinical program to investigate what may be the first potentially curative stem cell-based therapy for type 1 diabetes.

During his tenure as CEO Dr. Leiden established a signature program at Vertex to enhance STEAM education among students in Vertex's local communities, including an on-site Learning Lab, mentorship programs, internships and college scholarships. In 2017, Vertex announced a sustained corporate giving commitment of \$500 million over the next 10 years, of which \$50 million is focused on STEAM education.

Prior to joining Vertex, Dr. Leiden was a managing director at Clarus Ventures, a life sciences venture capital firm, from 2006 through January 2012. Dr. Leiden was President, Chief Operating Officer and Chief Scientific Officer of Abbott Laboratories, Pharmaceuticals Products Group, and a member of the board of directors of Abbott Laboratories from 2000 to 2006. At Abbott he led the development and commercialization of HUMIRA®. From 1987 to 2000, Dr. Leiden

#### Contact:

#### Jeffrey Leiden, M.D., Ph.D.

Executive Chairman

he/him/his

Vertex Pharmaceuticals Incorporated

50 Northern Avenue

Boston, MA 02210

+1 (617) 341-6100

VRTX.com

---

**Joined Vertex:** 2012

#### Education:

University of Chicago

#### Notable Recognitions:

EY Entrepreneur of the Year

*Boston* magazine's 100 Most Influential People in Boston

New Englander of the Year

STAT's Biopharma CEO of the Year

Academy of Distinguished Bostonians

*Forbes* Lifetime Achievement in BioPharma

## Jeffrey Leiden, M.D., Ph.D.

Executive Chairman



held several academic appointments, including the Rawson Professor of Medicine and Pathology and Chief of Cardiology and Director of the Cardiovascular Research Institute at the University of Chicago, the Elkan R. Blout Professor of Biological Sciences at the Harvard School of Public Health, and Professor of Medicine at Harvard Medical School. He is an elected member of both the American Academy of Arts and Sciences and the National Academy of Medicine.

Dr. Leiden serves as a director of Massachusetts Mutual Life Insurance Company and as chairman of Odyssey Therapeutics, a privately held company developing novel medicines for the treatment of cancer and autoimmune diseases, and Casana Health, a privately held home-health monitoring company. He is also a member of the MIT CEO Advisory Board, a member of the Harvard Medical School Board of Fellows, a director of the Massachusetts Competitive Partnership (MACP), and a strategic advisor for J.P. Morgan's Life Sciences Private Capital.

Dr. Leiden was previously a director and the non-executive vice chairman of the board of Shire plc, a specialty biopharmaceutical company, from 2006 to January 2012, a director of Quest Diagnostics, a medical diagnostics company, from December 2014 to May 2019, and chairman of the Massachusetts Competitive Partnership (MACP) from January 2020 to December 2022. Dr. Leiden received his M.D., Ph.D. and B.A. degrees from the University of Chicago.

During his tenure at Vertex, Dr. Leiden received a number of distinguished honors and awards for his contributions to the biomedical innovation ecosystem, STEAM education and Vertex's advances in CF research, including:

- Lifetime Achievement in BioPharma, *Forbes* (2020)
- America's Most Innovative Leaders, *Forbes* (2019)
- Star of STEM, Museum of Science (2019)
- Public Company of the Year, National Association of Corporate Directors, New England Division (2019)
- Power 50 Honoree, *Boston Business Journal* (2013, 2014, 2015, 2017, 2018, 2022)
- Service to Science Pharmaceutical Industry Leadership Award, National Disease Research Interchange (2018)
- Henri A. Termeer Innovative Leadership Award, Massachusetts Biotechnology Council (2018)
- STEM Corporate Leader of the Year Award, United Way Foundation (2018)
- 100 Most Influential People in Boston, *Boston* magazine (2018, 2020)
- Academy of Distinguished Bostonians, Greater Boston Chamber of Commerce (2018)
- Hope Award, Biomedical Science Careers Program (2018)
- New Englander of the Year, New England Council (2018)
- Biopharma CEO of the Year, *STAT News* (2018)
- IMPACT Award, New England Venture Capital Association (2017)
- EY Entrepreneur of the Year®, EY New England Region (2017)
- Uncork the Cure Award, Massachusetts Cystic Fibrosis Foundation (2015)
- MVP Award, Boomer Esiason Foundation (2014)